Analysts expect revenue declines at Amarin and Bicycle Therapeutics in third-quarter reports
Analysts expect quarterly revenue to fall at Amarin and Bicycle Therapeutics, which both report on October 28. Both are seen posting losses per share.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Earnings Preview, citing LSEG consensus data, Amarin Corporation PLC will report results on October 28 for the period ended September 30, 2026. The Dublin-based company is expected to post revenue of $43.711 million, down 12.0% from $49.67 million a year earlier. Two analysts forecast a loss of 2 cents per share, and the average rating on the stock is sell.
Bicycle Therapeutics PLC, based in Cambridge, is also expected to report on October 28, though that date is an estimate. Revenue is forecast at $6.069 million against $11.73 million a year ago, a 48.3% drop. Seven analysts see a loss of 43 cents per share, and their average rating is buy.
why it matters
Previews like these show what the market expects before results come out and contain no reported figures. Amarin's median 12-month target of $12.00 sits only slightly above its last close of $11.79, while Bicycle's $11.00 target is far above its $3.55 close. Analyst earnings estimates have not changed in the past three months, so the actual results will be the first real test of these forecasts.
tags
instruments
sources
- Amarin Corporation PLC expected to post a loss of 2 cents a share — Earnings Preview, 26 October 2026 at 13:03 UTC
- Bicycle Therapeutics PLC expected to post a loss of 43 cents a share — Earnings Preview, 26 October 2026 at 13:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗